Sight Sciences (SGHT)
Market Price (2/15/2026): $5.365 | Market Cap: $281.0 MilSector: Health Care | Industry: Life Sciences Tools & Services
Sight Sciences (SGHT)
Market Price (2/15/2026): $5.365Market Cap: $281.0 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% | Weak multi-year price returns2Y Excs Rtn is -18%, 3Y Excs Rtn is -121% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -45 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -60% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Chronic Ophthalmic Disease Management. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.4%, Rev Chg QQuarterly Revenue Change % is -1.2% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 19% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -41%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -42% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 58% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% | ||
| Key risksSGHT key risks include [1] adverse Medicare coverage decisions severely limiting reimbursement for its core OMNI and TearCare systems, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Chronic Ophthalmic Disease Management. |
| Weak multi-year price returns2Y Excs Rtn is -18%, 3Y Excs Rtn is -121% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -45 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -60% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.4%, Rev Chg QQuarterly Revenue Change % is -1.2% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 19% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -41%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -42% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 58% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Key risksSGHT key risks include [1] adverse Medicare coverage decisions severely limiting reimbursement for its core OMNI and TearCare systems, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Positive Financial Performance and Outlook: Sight Sciences reported strong preliminary unaudited financial highlights for the fourth quarter and full year ended December 31, 2025, showing an expected 7% increase in total revenue year-over-year for Q4 2025. This was preceded by the Q3 2025 earnings report in November, where the company raised its full-year 2025 revenue guidance to $76 million to $78 million and lowered its adjusted operating expense guidance, signaling improved financial health and operational discipline.
2. Significant Reimbursement Milestones and Expanded Market Access: The company achieved crucial reimbursement milestones for its TearCare system with First Coast Service Options and Novitas Solutions establishing permanent Medicare fee schedules, covering an estimated 10.4 million Medicare beneficiaries. Additionally, UnitedHealthcare's expanded coverage for the OMNI Surgical System, effective October 1, 2025, further broadened market access for their glaucoma treatment, contributing to increased ordering accounts for surgical glaucoma.
Show more
Stock Movement Drivers
Fundamental Drivers
The 5.9% change in SGHT stock from 10/31/2025 to 2/14/2026 was primarily driven by a 7.4% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.06 | 5.36 | 5.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 76 | 76 | -0.3% |
| P/S Multiple | 3.4 | 3.7 | 7.4% |
| Shares Outstanding (Mil) | 52 | 52 | -1.1% |
| Cumulative Contribution | 5.9% |
Market Drivers
10/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| SGHT | 5.9% | |
| Market (SPY) | -0.0% | 46.5% |
| Sector (XLV) | 9.3% | 37.2% |
Fundamental Drivers
The 61.0% change in SGHT stock from 7/31/2025 to 2/14/2026 was primarily driven by a 68.8% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.33 | 5.36 | 61.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 78 | 76 | -2.6% |
| P/S Multiple | 2.2 | 3.7 | 68.8% |
| Shares Outstanding (Mil) | 51 | 52 | -2.1% |
| Cumulative Contribution | 61.0% |
Market Drivers
7/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| SGHT | 61.0% | |
| Market (SPY) | 8.2% | 38.4% |
| Sector (XLV) | 21.4% | 27.5% |
Fundamental Drivers
The 91.4% change in SGHT stock from 1/31/2025 to 2/14/2026 was primarily driven by a 108.3% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.80 | 5.36 | 91.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 80 | 76 | -4.4% |
| P/S Multiple | 1.8 | 3.7 | 108.3% |
| Shares Outstanding (Mil) | 50 | 52 | -3.9% |
| Cumulative Contribution | 91.4% |
Market Drivers
1/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| SGHT | 91.4% | |
| Market (SPY) | 14.3% | 33.3% |
| Sector (XLV) | 8.8% | 26.3% |
Fundamental Drivers
The -53.4% change in SGHT stock from 1/31/2023 to 2/14/2026 was primarily driven by a -56.2% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.51 | 5.36 | -53.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 65 | 76 | 16.2% |
| P/S Multiple | 8.4 | 3.7 | -56.2% |
| Shares Outstanding (Mil) | 48 | 52 | -8.5% |
| Cumulative Contribution | -53.4% |
Market Drivers
1/31/2023 to 2/14/2026| Return | Correlation | |
|---|---|---|
| SGHT | -53.4% | |
| Market (SPY) | 74.0% | 26.6% |
| Sector (XLV) | 23.7% | 20.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SGHT Return | -48% | -31% | -58% | -29% | 118% | -32% | -84% |
| Peers Return | 14% | -15% | -7% | -18% | 33% | 7% | 5% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| SGHT Win Rate | 33% | 58% | 33% | 42% | 50% | 0% | |
| Peers Win Rate | 60% | 50% | 50% | 44% | 43% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SGHT Max Drawdown | -48% | -68% | -89% | -35% | -43% | -32% | |
| Peers Max Drawdown | -17% | -38% | -37% | -28% | -18% | -14% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, POAS, TMO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | SGHT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.7% | -25.4% |
| % Gain to Breakeven | 2931.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to A, ATEC, CERS, POAS, TMO
In The Past
Sight Sciences's stock fell -96.7% during the 2022 Inflation Shock from a high on 8/9/2021. A -96.7% loss requires a 2931.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Sight Sciences (SGHT)
AI Analysis | Feedback
- A Glaukos for comprehensive minimally invasive glaucoma surgery and therapeutic dry eye devices.
- A Dexcom for innovative devices treating chronic eye conditions like glaucoma and dry eye.
AI Analysis | Feedback
```html- OMNI Surgical System: A minimally invasive glaucoma surgery (MIGS) device used to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
- TearCare System: A wearable device that delivers localized heat to the eyelids for the treatment of dry eye disease caused by meibomian gland dysfunction (MGD).
AI Analysis | Feedback
Sight Sciences (SGHT) sells primarily to other companies within the healthcare sector, making it a business-to-business (B2B) operation.
Due to the nature of the medical device market and Sight Sciences' sales strategy, the company does not typically disclose specific individual "major customer companies" (e.g., large hospital chains or purchasing groups) that account for a material portion of its revenue in its public filings. This is common for medical device manufacturers, as their sales are often distributed across a broad base of healthcare providers rather than concentrated with a few large entities. In fact, Sight Sciences states in its public filings that it does not believe the loss of any single customer would have a material adverse effect on its business because it has a large number of customers.
Sight Sciences' products, such as the OMNI Surgical System (for glaucoma) and the TearCare System (for dry eye disease), are sold to a fragmented market of ophthalmic professionals and facilities. Therefore, its primary customer categories are:
- Ophthalmology Practices: Individual or group practices specializing in eye care, where ophthalmologists perform surgical procedures for glaucoma and in-office treatments for dry eye disease.
- Ambulatory Surgical Centers (ASCs): Outpatient facilities where ophthalmic surgical procedures, including those utilizing Sight Sciences' OMNI Surgical System, are performed.
- Hospitals: Healthcare institutions that have ophthalmology departments or surgical units performing eye-related procedures.
- Optometry Practices: Practices where optometrists manage and treat dry eye disease, often utilizing the TearCare System.
In international markets, Sight Sciences also utilizes third-party distributors who then sell its products to similar healthcare providers and facilities.
AI Analysis | Feedback
null
AI Analysis | Feedback
Paul Badawi, Founder, Chief Executive Officer
Paul Badawi is a co-founder of Sight Sciences, Inc. and has served as its President, CEO, and Director since the company's founding in 2011. Prior to launching Sight Sciences, he led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm, where he managed a portfolio of 12 medical device investments. While at 3i Group, he served as a lead investor and board member for companies such as Ulthera (acquired by Merz), Xthetix (acquired by Johnson & Johnson), and NeoGuide (acquired by Intuitive Surgical), among others. He holds an MBA from the University of California, Los Angeles, and a BS in Biological Sciences from the University of Chicago.
James Rodberg, Chief Financial Officer
James Rodberg was appointed Chief Financial Officer of Sight Sciences, effective November 5, 2025. He joined Sight Sciences in early 2021 as Vice President of Finance and Corporate Controller and also served as interim CFO in 2023. His previous experience includes roles at nVent Electric, Abbott Laboratories, and St. Jude Medical, where he held increasingly senior finance and accounting positions prior to St. Jude Medical's acquisition by Abbott. Rodberg has 20 years of experience in public accounting and company finance leadership.
Alison Bauerlein, Chief Operating Officer
Alison Bauerlein was named Chief Operating Officer of Sight Sciences, a newly created position, effective November 5, 2025, succeeding herself as CFO. She joined Sight Sciences in April 2023 as CFO. Prior to Sight Sciences, Bauerlein co-founded Inogen, a medical technology company, where she served as CFO from 2009 to 2021. During her tenure at Inogen, she was instrumental in scaling the company from a startup to over $350 million in annual sales. She brings experience leading global finance and accounting functions, investor relations, and business development.
David Badawi, Founder, Chief Technology Officer
David Badawi is a co-founder and Chief Technology Officer of Sight Sciences. He is the brother of CEO Paul Badawi. He is also a co-inventor of several of the company's key products, including the OMNI® Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare® System.
Sam Park, Chief Operating Officer
Sam Park joined Sight Sciences as Chief Operating Officer in June 2020. He brings over 25 years of medical device experience, including executive-level leadership roles at several companies that were subsequently acquired. These include SurgRx (acquired by Johnson & Johnson's Ethicon Endo-Surgery division), Novacept (acquired by Cytyc), Arthrocare (acquired by Smith+Nephew), Origin Medsystems (acquired by Eli Lily and Company), and CardioGenesis (acquired by CryoLife).
AI Analysis | Feedback
The key risks to Sight Sciences (SGHT) primarily revolve around reimbursement challenges, competitive market dynamics, and cost pressures from tariffs.
- Medicare Coverage Restrictions and Reimbursement Challenges: A critical risk for Sight Sciences stems from changes in Medicare Local Coverage Determinations (LCDs) which became effective in mid-2024. These policies have eliminated reimbursement for performing multiple minimally invasive glaucoma surgeries (MIGS) concurrently with cataract procedures in most U.S. states, directly impacting the utilization of the company's flagship OMNI Surgical System. This has led to projected revenue declines for the surgical glaucoma segment. Similarly, the TearCare System, designed for dry eye disease, has underperformed significantly due to delays in reimbursement, particularly the lack of Medicare coverage for the procedure, causing a substantial drop in its revenue.
- Competitive Pressures: Sight Sciences operates within a highly competitive glaucoma surgery market where surgeons have numerous effective treatment options. While the company's OMNI product is recognized for its efficacy in reducing intraocular pressure, concerns exist regarding its ability to continuously gain market share and increase average selling prices. This challenge is partly attributed to limitations physicians may face in using multiple MIGS devices and potentially less attractive economic factors associated with OMNI. The company faces competition from established players like Glaukos, Alcon, Nova Eye Medical, MicroSurgical Technology, and New World Medical.
- Tariffs and Cost Pressures: Sight Sciences is exposed to U.S. tariffs on components sourced from China, which are anticipated to add several million dollars in costs to its Surgical Glaucoma segment in 2025. Although the company is actively expanding its manufacturing capabilities to reduce supply chain vulnerabilities and mitigate these costs, tariffs remain a notable near-term financial burden.
AI Analysis | Feedback
The recent market entry of novel pharmacological treatments for evaporative dry eye disease poses an emerging threat to Sight Sciences' TearCare System. For example, Bausch + Lomb's Miebo (perfluorohexyloctane ophthalmic solution), approved by the FDA in May 2023, offers a new mechanism of action to reduce tear evaporation, a primary symptom addressed by treating meibomian gland dysfunction (MGD) with devices like TearCare. While TearCare directly treats MGD, a leading cause of evaporative dry eye, a highly effective and easily administered eye drop like Miebo could potentially capture a segment of the market, reduce the perceived need for device-based interventions for some patients, or alter the treatment pathway, thus impacting the adoption and market share of the TearCare System.
AI Analysis | Feedback
Sight Sciences (SGHT) focuses on two main product areas: surgical glaucoma and dry eye disease.
Surgical Glaucoma Products (OMNI Surgical System, SION Surgical Instrument)
Sight Sciences' OMNI Surgical System and SION Surgical Instrument address the Minimally Invasive Glaucoma Surgery (MIGS) market.
- The global minimally invasive glaucoma surgery (MIGS) devices market was estimated at USD 539.6 million in 2023 and is anticipated to grow to USD 781.2 million by 2030, with a compound annual growth rate (CAGR) of 5.36% from 2024 to 2030.
- Another estimate projects the global MIGS devices market to reach approximately USD 1.8 billion in 2025 and expand at a CAGR of around 20% through 2033.
- For the U.S. market, the total addressable market for Combination Cataract MIGS is approximately USD 1 billion, and for Standalone MIGS, it is nearly USD 5 billion.
- North America held the largest share (36%) of the MIGS devices market in 2023.
Dry Eye Disease Products (TearCare System)
The TearCare System from Sight Sciences addresses the dry eye disease (DED) market, specifically evaporative dry eye disease due to meibomian gland dysfunction (MGD).
- The global dry eye disease treatment market is valued at USD 6.36 billion in 2025 and is forecast to reach USD 7.77 billion by 2030, with a CAGR of 4.09%.
- Another projection estimates the global market for dry eye syndrome therapeutics to reach USD 8.5 billion by 2033, growing at a CAGR of 4.5% over the forecast period.
- The dry eye disease market size was valued at over USD 6 billion in 2022 and is projected to reach around USD 12.3 billion by 2032.
- In North America, the dry eye disease market was valued at USD 2.4 billion in 2022. The United States has the largest patient pool for dry eye disease and represents the biggest market for its treatment.
AI Analysis | Feedback
Sight Sciences (SGHT) anticipates several key drivers to fuel its revenue growth over the next 2-3 years:
- Accelerated Commercialization of TearCare with Reimbursed Market Access: A significant driver is the expanded Medicare coverage for the TearCare System. The establishment of jurisdiction-wide pricing with First Coast Service Options and Novitas Solutions, covering 10.4 million Medicare beneficiaries, is expected to enable Sight Sciences to pioneer the reimbursed market for interventional dry eye procedures. The company is actively focusing on accelerating commercialization efforts in these newly covered regions.
- Continued Growth of the OMNI Surgical System in Glaucoma: The Surgical Glaucoma segment, driven by the OMNI Surgical System, demonstrated a 6% revenue increase in Q3 2025, propelled by an increase in ordering accounts and average selling prices. Management projects sustained growth for OMNI in both combination cataract and standalone use cases throughout 2025 and into 2026, emphasizing its differentiated clinical profile.
- Expansion of Ordering Accounts and Increased Product Utilization: For the Surgical Glaucoma segment, the number of ordering accounts reached a record high, indicating growing market penetration. The company's strategy involves strengthening commercial execution and driving further adoption of its OMNI technology. For TearCare, the focus is on education, identification, and activation of accounts in new jurisdictions with established reimbursement, aiming to substantially increase utilization.
- Launch of Next-Generation OMNI: Sight Sciences has a robust pipeline of interventional glaucoma and dry eye technologies, including the planned release of a next-generation OMNI product in the first half of 2025. This new product introduction is expected to contribute to future revenue growth by offering enhanced solutions to the market.
- Advancement of Clinical Data and Market Development for TearCare: The anticipated publication of clinical data and a budget impact model for TearCare is expected to accelerate its adoption and growth in 2025. Furthermore, the inclusion of the TearCare System in global dry eye guidelines is a significant milestone that supports broader market acceptance and access.
AI Analysis | Feedback
Share Issuance
- In July 2021, Sight Sciences completed its Initial Public Offering (IPO), issuing 11,500,000 shares of common stock at an initial public offering price of $24.00 per share.
- The IPO generated approximately $276 million in gross proceeds.
Inbound Investments
- Sight Sciences closed an over $30 million Series E Preferred Stock financing round in March 2020, led by D1 Capital Partners.
- A Series E round on December 3, 2020, brought in an additional $23.2 million, with Janus Henderson Investors as the lead investor.
Capital Expenditures
- Sight Sciences reported capital expenditures of $210,000 for the quarter ending June 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Sight Sciences Earnings Notes | 12/16/2025 | |
| Would You Still Hold Sight Sciences Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.36 |
| Mkt Cap | 2.0 |
| Rev LTM | 728 |
| Op Inc LTM | -9 |
| FCF LTM | 0 |
| FCF 3Y Avg | -15 |
| CFO LTM | 35 |
| CFO 3Y Avg | -12 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.7% |
| Rev Chg 3Y Avg | 6.1% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Mgn LTM | -4.8% |
| Op Mgn 3Y Avg | -11.9% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 4.8% |
| CFO/Rev 3Y Avg | -7.5% |
| FCF/Rev LTM | 0.1% |
| FCF/Rev 3Y Avg | -9.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.0 |
| P/S | 3.7 |
| P/EBIT | -6.8 |
| P/E | -6.1 |
| P/CFO | 24.9 |
| Total Yield | -3.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.3% |
| D/E | 0.2 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -19.0% |
| 3M Rtn | -19.4% |
| 6M Rtn | 4.7% |
| 12M Rtn | 8.2% |
| 3Y Rtn | -20.5% |
| 1M Excs Rtn | -17.2% |
| 3M Excs Rtn | -23.5% |
| 6M Excs Rtn | -0.4% |
| 12M Excs Rtn | -3.3% |
| 3Y Excs Rtn | -87.9% |
Price Behavior
| Market Price | $5.36 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 07/15/2021 | |
| Distance from 52W High | -40.8% | |
| 50 Days | 200 Days | |
| DMA Price | $7.21 | $4.97 |
| DMA Trend | up | indeterminate |
| Distance from DMA | -25.7% | 7.9% |
| 3M | 1YR | |
| Volatility | 58.1% | 82.0% |
| Downside Capture | 292.33 | 141.81 |
| Upside Capture | 108.81 | 194.35 |
| Correlation (SPY) | 44.8% | 33.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.94 | 1.34 | 2.85 | 2.82 | 1.38 | 1.66 |
| Up Beta | 5.21 | 4.41 | 3.90 | 3.70 | 1.69 | 1.43 |
| Down Beta | 1.45 | 1.22 | 2.16 | 2.12 | 0.39 | 1.34 |
| Up Capture | -272% | -69% | 423% | 537% | 390% | 689% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 19 | 31 | 55 | 115 | 345 |
| Down Capture | 209% | 229% | 211% | 189% | 127% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 21 | 29 | 62 | 124 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGHT | |
|---|---|---|---|---|
| SGHT | 151.6% | 80.4% | 1.48 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 25.6% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 33.5% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | -6.9% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 4.0% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 26.9% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 21.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGHT | |
|---|---|---|---|---|
| SGHT | -28.2% | 91.2% | 0.06 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 25.3% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 33.6% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 4.3% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 5.4% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 25.7% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SGHT | |
|---|---|---|---|---|
| SGHT | -15.2% | 91.2% | 0.06 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 25.3% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 33.6% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 4.3% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 5.4% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 25.7% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 16.4% | 41.0% | 66.8% |
| 8/7/2025 | 19.4% | 19.7% | 3.9% |
| 3/5/2025 | 2.9% | 11.2% | -7.9% |
| 11/7/2024 | -9.6% | -17.5% | -14.7% |
| 8/1/2024 | -15.0% | -21.4% | -8.8% |
| 3/7/2024 | 6.1% | -4.1% | 17.4% |
| 11/7/2023 | -1.9% | -1.9% | 26.2% |
| 8/3/2023 | 7.6% | -2.5% | -18.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 4 | 5 |
| # Negative | 7 | 10 | 9 |
| Median Positive | 7.6% | 21.1% | 26.2% |
| Median Negative | -6.4% | -6.8% | -18.7% |
| Max Positive | 34.9% | 41.0% | 66.8% |
| Max Negative | -15.0% | -21.6% | -44.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/24/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Badawi, Paul | President and CEO | Direct | Sell | 1062026 | 7.43 | 25,356 | 188,395 | 44,112,995 | Form |
| 2 | Badawi, Paul | President and CEO | Direct | Sell | 1062026 | 7.48 | 11,870 | 88,788 | 44,321,064 | Form |
| 3 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 1062026 | 7.82 | 9,385 | 73,391 | 1,933,143 | Form |
| 4 | Hayden, Jeremy B | Chief Legal Officer | Direct | Sell | 1062026 | 7.48 | 1,785 | 13,352 | 1,835,742 | Form |
| 5 | Badawi, David | Chief Technology Officer | Direct | Sell | 1062026 | 7.43 | 2,914 | 21,651 | 14,294,243 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.